Hologic, Inc. $HOLX Stock Holdings Increased by American Century Companies Inc.

American Century Companies Inc. increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,848,892 shares of the medical equipment provider’s stock after purchasing an additional 196,898 shares during the quarter. American Century Companies Inc. owned approximately 0.83% of Hologic worth $124,782,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Hologic during the 3rd quarter valued at $3,611,000. Fifth Lane Capital LP acquired a new stake in Hologic during the third quarter valued at $202,000. R Squared Ltd purchased a new position in Hologic in the third quarter valued at about $646,000. DNB Asset Management AS increased its position in Hologic by 1.6% in the 3rd quarter. DNB Asset Management AS now owns 264,193 shares of the medical equipment provider’s stock worth $17,830,000 after purchasing an additional 4,179 shares during the last quarter. Finally, Choreo LLC raised its stake in shares of Hologic by 9.6% during the 3rd quarter. Choreo LLC now owns 4,228 shares of the medical equipment provider’s stock worth $285,000 after purchasing an additional 372 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HOLX shares. Morgan Stanley increased their price objective on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and decreased their price objective for the stock from $79.00 to $78.00 in a report on Monday, January 5th. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and an average price target of $78.42.

Hologic Stock Up 0.2%

HOLX stock opened at $75.36 on Monday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.49. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The company has a market cap of $16.82 billion, a PE ratio of 31.40, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. The business’s 50-day simple moving average is $74.95 and its 200 day simple moving average is $72.16.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.